Cargando…

COMPLICATIONS AND MIDTERM OUTCOMES OF HEMIARTHROPLASTY IN HEMODIALYSIS PATIENTS

OBJECTIVE: The aim of this study was to evaluate the functional results, complications, and morbidity and mortality rates in patients with end-stage chronic renal failure (ESCRF) with collum femoris fractures who were treated with hemiarthroplasty. METHODS: From 2005 to 2013, patients with ESCRF adm...

Descripción completa

Detalles Bibliográficos
Autores principales: SALDUZ, AHMET, POLAT, GÖKHAN, AKGÜL, TURGUT, ERGIN, OMER NACI, ŞAHIN, KORAY, YAZICIOĞLU, ÖNDER
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ATHA EDITORA 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608744/
https://www.ncbi.nlm.nih.gov/pubmed/29081710
http://dx.doi.org/10.1590/1413-785220172505167473
_version_ 1783265484923207680
author SALDUZ, AHMET
POLAT, GÖKHAN
AKGÜL, TURGUT
ERGIN, OMER NACI
ŞAHIN, KORAY
YAZICIOĞLU, ÖNDER
author_facet SALDUZ, AHMET
POLAT, GÖKHAN
AKGÜL, TURGUT
ERGIN, OMER NACI
ŞAHIN, KORAY
YAZICIOĞLU, ÖNDER
author_sort SALDUZ, AHMET
collection PubMed
description OBJECTIVE: The aim of this study was to evaluate the functional results, complications, and morbidity and mortality rates in patients with end-stage chronic renal failure (ESCRF) with collum femoris fractures who were treated with hemiarthroplasty. METHODS: From 2005 to 2013, patients with ESCRF admitted to our hospital with collum femoris fracture and treated with hemiarthroplasty were retrospectively evaluated, and 44 hips in 42 patients were included in the study. Duration of hospital stay, bleeding, complications, morbidity and mortality were recorded for each patient. At the last control evaluation, patients were assessed via pelvis x-ray and functional status according to Harris Hip Score (HHS). RESULTS: Patients required a mean 2.7 units of erythrocyte suspension. Mean hospital stay was 19.74 days. The most common complication was bleeding. The complication rate was 38.1%; mortality rate at first-year follow-up was 42.8%, and mean HHS was 74.5. CONCLUSION: Collum femoris fractures are more common in ESCRF patients due to metabolic bone disease, and these patients had many comorbidities which may exacerbate high complication and mortality rates. Orthopedic surgeons should consider these higher complication rates and inform patients about the consequences of this treatment. Level of Evidence IV, Case Series.
format Online
Article
Text
id pubmed-5608744
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher ATHA EDITORA
record_format MEDLINE/PubMed
spelling pubmed-56087442017-10-27 COMPLICATIONS AND MIDTERM OUTCOMES OF HEMIARTHROPLASTY IN HEMODIALYSIS PATIENTS SALDUZ, AHMET POLAT, GÖKHAN AKGÜL, TURGUT ERGIN, OMER NACI ŞAHIN, KORAY YAZICIOĞLU, ÖNDER Acta Ortop Bras Original Article OBJECTIVE: The aim of this study was to evaluate the functional results, complications, and morbidity and mortality rates in patients with end-stage chronic renal failure (ESCRF) with collum femoris fractures who were treated with hemiarthroplasty. METHODS: From 2005 to 2013, patients with ESCRF admitted to our hospital with collum femoris fracture and treated with hemiarthroplasty were retrospectively evaluated, and 44 hips in 42 patients were included in the study. Duration of hospital stay, bleeding, complications, morbidity and mortality were recorded for each patient. At the last control evaluation, patients were assessed via pelvis x-ray and functional status according to Harris Hip Score (HHS). RESULTS: Patients required a mean 2.7 units of erythrocyte suspension. Mean hospital stay was 19.74 days. The most common complication was bleeding. The complication rate was 38.1%; mortality rate at first-year follow-up was 42.8%, and mean HHS was 74.5. CONCLUSION: Collum femoris fractures are more common in ESCRF patients due to metabolic bone disease, and these patients had many comorbidities which may exacerbate high complication and mortality rates. Orthopedic surgeons should consider these higher complication rates and inform patients about the consequences of this treatment. Level of Evidence IV, Case Series. ATHA EDITORA 2017 /pmc/articles/PMC5608744/ /pubmed/29081710 http://dx.doi.org/10.1590/1413-785220172505167473 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Original Article
SALDUZ, AHMET
POLAT, GÖKHAN
AKGÜL, TURGUT
ERGIN, OMER NACI
ŞAHIN, KORAY
YAZICIOĞLU, ÖNDER
COMPLICATIONS AND MIDTERM OUTCOMES OF HEMIARTHROPLASTY IN HEMODIALYSIS PATIENTS
title COMPLICATIONS AND MIDTERM OUTCOMES OF HEMIARTHROPLASTY IN HEMODIALYSIS PATIENTS
title_full COMPLICATIONS AND MIDTERM OUTCOMES OF HEMIARTHROPLASTY IN HEMODIALYSIS PATIENTS
title_fullStr COMPLICATIONS AND MIDTERM OUTCOMES OF HEMIARTHROPLASTY IN HEMODIALYSIS PATIENTS
title_full_unstemmed COMPLICATIONS AND MIDTERM OUTCOMES OF HEMIARTHROPLASTY IN HEMODIALYSIS PATIENTS
title_short COMPLICATIONS AND MIDTERM OUTCOMES OF HEMIARTHROPLASTY IN HEMODIALYSIS PATIENTS
title_sort complications and midterm outcomes of hemiarthroplasty in hemodialysis patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608744/
https://www.ncbi.nlm.nih.gov/pubmed/29081710
http://dx.doi.org/10.1590/1413-785220172505167473
work_keys_str_mv AT salduzahmet complicationsandmidtermoutcomesofhemiarthroplastyinhemodialysispatients
AT polatgokhan complicationsandmidtermoutcomesofhemiarthroplastyinhemodialysispatients
AT akgulturgut complicationsandmidtermoutcomesofhemiarthroplastyinhemodialysispatients
AT erginomernaci complicationsandmidtermoutcomesofhemiarthroplastyinhemodialysispatients
AT sahinkoray complicationsandmidtermoutcomesofhemiarthroplastyinhemodialysispatients
AT yaziciogluonder complicationsandmidtermoutcomesofhemiarthroplastyinhemodialysispatients